secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2026-05-27T11:30:35+00:00
Accession:  0001628280-26-038307
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences reports PBGENE-HBV eliminates cccDNA in biopsies; pgRNA loss in 100% of patients
--------------------------------------------------------------------------------

- Liver biopsy data show 1-log reduction in cccDNA transcripts after two doses at 0.4 mg/kg; indels inactivate remaining <1%.
- pgRNA established as biomarker; 100% of patients (n=6) with detectable pgRNA achieved loss, confirmed by biopsy.
- HBsAg declines in 100% of patients (n=15); first patient maintains durable decline for over 12 months.
- Safety: No DLTs; manageable LNP-related AEs; mitigation protocol resolved Grade 3 hypotension events with no recurrences.
- Next steps: expand enrollment, collect additional biopsies, design Part 2 expansion; update expected by end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026038307/0001628280-26-038307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026038307/dtil-20260527.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-038307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer